Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | MPO | P05164 | 7/20 | 0.34 |
| ▸ | XDH | P47989 | 4/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.34 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 3/20 | 0.33 |
| ▸ | CA1 | P00915 | 3/20 | 0.33 |
| ▸ | CA2 | P00918 | 3/20 | 0.33 |
| ▸ | QPCT | Q16769 | 3/20 | 0.32 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26037651 | 0.75 | CA9 (0.31) | L3MBTL1MPOALDH1A1TSHRHTT | |
| SCHEMBL6471986 | 0.73 | SLC9A1 (0.42) | ALDH1A1SLC9A1 | |
| SCHEMBL26034573 | 0.71 | ALDH1A1 (0.35) | L3MBTL1ALDH1A1HTTRXFP1QPCT | |
| SCHEMBL15110502 | 0.69 | SLC9A1 (0.51) | SLC9A1QPCTADORA2A | |
| SCHEMBL16581427 | 0.65 | ADORA2A (0.48) | L3MBTL1SLC9A1ADORA2A | |
| SCHEMBL3792986 | 0.64 | SLC9A1 (0.47) | SLC9A1ADORA2A | |
| SCHEMBL28021077 | 0.63 | ATAD2 (0.34) | ALDH1A1SLC9A1 | |
| SCHEMBL8656134 | 0.63 | ALDH1A1 (0.47) | L3MBTL1XDHALDH1A1HTTHSD17B10 | |
| SCHEMBL4657306 | 0.63 | MAPT (0.42) | L3MBTL1ALDH1A1TSHRHTTHSD17B10 | |
| SCHEMBL8761973 | 0.60 | ALDH1A1 (0.40) | ALDH1A1TSHRCA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230273455-A1 | OPTICALLY ACTIVE DEVICES | JOHNSON & JOHNSON SURGICAL VISION INC (US) | 2023-08-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230273455-A1 | OPTICALLY ACTIVE DEVICES | PDE6C, PDE6A, PDE6D | L3MBTL1 4743/4885MPO 146/4885XDH 1164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.